Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa.
The long-term safety and immunogenicity of a polyvalent Pseudomonas aeruginosa conjugate vaccine was evaluated in 30 noncolonized cystic fibrosis patients. Four doses were administered over 3 years, and patients were followed for a mean of 38 months. No acute or long-term adverse effects were noted. Immunization engendered a significant antibody response to all vaccine components. A decline in titers during year 3 of observation was associated with a marked rise in the isolation of P. aeruginosa. This organism was isolated repeatedly from the respiratory tract of 4 patients and only once from 7 patients. The remaining patients were repeatedly culture-negative. Only 1 patient showed clinical deterioration associated with multiple isolations of P. aeruginosa.
Cryz
S J
SJ
Swiss Serum and Vaccine Institute, Inselspital, University of Berne.
Wedgwood
J
J
Lang
A B
AB
Ruedeberg
A
A
Que
J U
JU
Fürer
E
E
Schaad
U B
UB
D000293:Adolescent; D000328:Adult; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications* / Q000276:immunology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011552:Pseudomonas Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*
D001428:Bacterial Vaccines